The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
04 08 2020
Historique:
received: 17 10 2019
revised: 22 06 2020
accepted: 10 07 2020
entrez: 7 8 2020
pubmed: 7 8 2020
medline: 4 5 2021
Statut: ppublish

Résumé

PARP inhibitors (PARPi) cause synthetic lethality in BRCA-deficient tumors. Whether specific vulnerabilities to PARPi exist beyond BRCA mutations and related defects in homology-directed repair (HDR) is not well understood. Here, we identify the ubiquitin E3 ligase TRIP12 as negative regulator of PARPi sensitivity. We show that TRIP12 controls steady-state PARP1 levels and limits PARPi-induced cytotoxic PARP1 trapping. Upon loss of TRIP12, elevated PARPi-induced PARP1 trapping causes increased DNA replication stress, DNA damage, cell cycle arrest, and cell death. Mechanistically, we demonstrate that TRIP12 binds PARP1 via a central PAR-binding WWE domain and, using its carboxy-terminal HECT domain, catalyzes polyubiquitylation of PARP1, triggering proteasomal degradation and preventing supra-physiological PARP1 accumulation. Further, in cohorts of breast and ovarian cancer patients, PARP1 abundance is negatively correlated with TRIP12 expression. We thus propose TRIP12 as regulator of PARP1 stability and PARPi-induced PARP trapping, with potential implications for PARPi sensitivity and resistance.

Identifiants

pubmed: 32755579
pii: S2211-1247(20)30970-0
doi: 10.1016/j.celrep.2020.107985
pmc: PMC7408484
pii:
doi:

Substances chimiques

Carrier Proteins 0
Mutagens 0
Poly(ADP-ribose) Polymerase Inhibitors 0
Poly Adenosine Diphosphate Ribose 26656-46-2
TRIP12 protein, human EC 2.3.2.26
Ubiquitin-Protein Ligases EC 2.3.2.27
PARP1 protein, human EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30
Proteasome Endopeptidase Complex EC 3.4.25.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107985

Subventions

Organisme : European Research Council
ID : 714326
Pays : International

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests M.G. and M.A. are listed as inventors on a UZH patent application for determining PARPi responsiveness.

Références

Lancet. 2010 Jul 24;376(9737):235-44
pubmed: 20609467
Cell Res. 2019 May;29(5):347-364
pubmed: 30948788
Science. 2016 Oct 7;354(6308):
pubmed: 27846469
J Clin Oncol. 2010 May 20;28(15):2512-9
pubmed: 20406929
Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641
pubmed: 30976793
Cell. 2009 Feb 6;136(3):420-34
pubmed: 19203578
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110
Cancers (Basel). 2018 Dec 04;10(12):
pubmed: 30518089
Nucleic Acids Res. 2013 Feb 1;41(3):1698-710
pubmed: 23268447
Nat Rev Mol Cell Biol. 2012 Jun 20;13(7):411-24
pubmed: 22713970
EMBO J. 2019 Aug 15;38(16):e101379
pubmed: 31267591
Mol Cell. 2019 Feb 21;73(4):670-683.e12
pubmed: 30639241
N Engl J Med. 2016 Sep 22;375(12):1109-12
pubmed: 27653561
Annu Rev Biochem. 2015;84:227-63
pubmed: 25747399
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Nat Cell Biol. 2011 May;13(5):623-9
pubmed: 21478859
Cancer Res. 2012 Nov 1;72(21):5588-99
pubmed: 23118055
Nat Commun. 2015 Aug 19;6:8088
pubmed: 26286827
Nature. 2010 Mar 25;464(7288):624-7
pubmed: 20208519
Cell Cycle. 2012 Oct 15;11(20):3837-50
pubmed: 22983061
Mol Cell. 2018 Mar 15;69(6):1046-1061.e5
pubmed: 29547717
Nature. 2018 Jul;559(7713):285-289
pubmed: 29973717
Science. 2002 Jul 12;297(5579):259-63
pubmed: 12114629
DNA Repair (Amst). 2019 Mar;75:48-59
pubmed: 30743082
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Nucleic Acids Res. 2019 May 7;47(8):3811-3827
pubmed: 30799503
Cancer Discov. 2013 Oct;3(10):1108-12
pubmed: 24124232
J Clin Invest. 2018 May 1;128(5):1727-1730
pubmed: 29664016
Cancer Res. 2016 Aug 1;76(15):4516-24
pubmed: 27261505
Mol Cell. 2018 Jul 19;71(2):319-331.e3
pubmed: 29983321
Nature. 2015 Jan 8;517(7533):223-6
pubmed: 25327252
J Biol Chem. 2012 Apr 13;287(16):12975-84
pubmed: 22337872
J Biol Chem. 2009 Jan 16;284(3):1540-9
pubmed: 19028681
J Clin Invest. 2018 May 1;128(5):2116-2126
pubmed: 29509546
Cell. 2012 Aug 17;150(4):697-709
pubmed: 22884692
Sci Transl Med. 2016 Oct 26;8(362):362ps17
pubmed: 27797957
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Annu Rev Cancer Biol. 2018 Mar;2:313-336
pubmed: 30345412
Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621
pubmed: 28676700
Front Genet. 2016 Apr 19;7:63
pubmed: 27148359
J Proteome Res. 2015 Jun 5;14(6):2707-13
pubmed: 25873244
Nat Rev Mol Cell Biol. 2015 Apr;16(4):207-20
pubmed: 25714681
Mol Cell. 2015 Dec 3;60(5):742-754
pubmed: 26626479
Nat Commun. 2018 Jul 11;9(1):2678
pubmed: 29992957
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
J Clin Oncol. 2020 Apr 10;38(11):1164-1174
pubmed: 32073956
EMBO J. 2016 Jan 4;35(1):6-23
pubmed: 26628622
Diagnostics (Basel). 2019 Aug 01;9(3):
pubmed: 31374917
Mol Cells. 2018 Aug 31;41(8):799-807
pubmed: 30037213
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
Genes Dev. 2012 Feb 1;26(3):235-40
pubmed: 22267412
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Cancer Cell. 2016 Oct 10;30(4):637-650
pubmed: 27728808
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14103-8
pubmed: 21825151
Nucleic Acids Res. 2016 Feb 18;44(3):993-1006
pubmed: 26673700
Genes Dev. 2017 Jan 15;31(2):101-126
pubmed: 28202539
Cell Syst. 2017 Oct 25;5(4):386-398.e4
pubmed: 29032074

Auteurs

Marco Gatti (M)

Department of Molecular Mechanisms of Disease, University of Zurich, Zurich 8057, Switzerland.

Ralph Imhof (R)

Department of Molecular Mechanisms of Disease, University of Zurich, Zurich 8057, Switzerland.

Qingyao Huang (Q)

Institute of Molecular Life Sciences, University of Zurich, Zurich 8057, Switzerland.

Michael Baudis (M)

Institute of Molecular Life Sciences, University of Zurich, Zurich 8057, Switzerland.

Matthias Altmeyer (M)

Department of Molecular Mechanisms of Disease, University of Zurich, Zurich 8057, Switzerland. Electronic address: matthias.altmeyer@uzh.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH